uniQure (NASDAQ:QURE) Director Robert Gut Sells 25,613 Shares

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 25,613 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Robert Gut also recently made the following trade(s):

• On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $22.35 on Thursday. The company has a market capitalization of $1.39 billion, a PE ratio of -5.09 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The company’s fifty day moving average price is $24.98 and its 200 day moving average price is $27.69. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. On average, research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on QURE. Mizuho cut their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. William Blair reissued a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Benchmark restated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. The Goldman Sachs Group reduced their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus dropped their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.82.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at about $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in uniQure in the 3rd quarter valued at about $50,000. FNY Investment Advisers LLC raised its holdings in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.